CD44 and Hyaluronan-mediated motility receptor (RHAMM) (CD44 / RHAMM)

CD44 and RHAMM (Receptor for Hyaluronan-Mediated Motility) are the primary cell surface receptors for hyaluronan (HA), a major glycosaminoglycan component of the extracellular matrix. While CD44 is a transmembrane glycoprotein involved in cell-cell and cell-matrix adhesion, RHAMM is a multifunctional protein that can localize to the cell surface, cytoplasm, and nucleus, where it regulates microtubule dynamics and mitotic spindle formation. These two receptors often function synergistically, forming signaling complexes with ERK1/2 and other kinases to drive cell motility, survival, and proliferation. In pathological contexts, the overexpression of CD44 and RHAMM is strongly associated with tumor progression, metastasis, and chronic inflammation. Because they are frequently upregulated in aggressive cancers and cancer stem cells, they are prominent targets for therapeutic intervention. Current drug development strategies include monoclonal antibodies to block HA binding, peptide inhibitors to disrupt receptor-ligand interactions, and RHAMM-targeted vaccines designed to stimulate an immune response against malignant cells. However, therapeutic targeting is complicated by the wide expression of CD44 in normal tissues and the dual roles these proteins can play in different tissue environments.

Other names

CD44 antigenHMMRCD168Pgp-1Hermes antigenH-CAMReceptor for Hyaluronan-Mediated MotilityIntracellular hyaluronic acid-binding protein (IHABP)HUTCH-1ECMR-III

Inhibition of hyaluronan binding, disruption of CD44-RHAMM-ERK1/2 signaling complexes, receptor internalization, antibody-dependent cellular cytotoxicity (ADCC), and induction of T-cell responses against RHAMM-expressing cells.